Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07155226 · ClinicalTrials.gov registry record · Phase 1

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

A Phase 1 study of Higher-risk Myelodysplastic Syndromes and Acute Lymphoblastic Leukaemia, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
84
Enrollment target
20
Study locations

NCT07155226: Recruiting Phase 1 study of Higher-risk Myelodysplastic Syndromes and Acute Lymphoblastic Leukaemia, sponsored by AstraZeneca.

NCT07155226 is a Phase 1 study of Higher-risk Myelodysplastic Syndromes and Acute Lymphoblastic Leukaemia that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 84 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07155226, a Phase 1 study of Higher-risk Myelodysplastic Syndromes and Acute Lymphoblastic Leukaemia, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
84 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.

Primary Outcome

Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.

Conditions Studied

Higher-risk Myelodysplastic Syndromes Acute Lymphoblastic Leukaemia Acute Myeloid Leukaemia

Interventions

  • DRUG AZD3632
  • DRUG Posaconazole

Study Locations (20)

Other

  • Research Site - Fitzroy
  • Research Site - Perth
  • Research Site - Copenhagen
  • Research Site - Dresden
  • Research Site - Frankfurt A. Main
  • Research Site - Halle
  • Research Site - Heidelberg
  • Research Site - München
  • Research Site - Ulm
  • Research Site - Bologna
  • Research Site - Ravenna
  • Research Site - Bunkyō City
  • Research Site - Kashiwa

Illinois

  • Research Site - Decatur

New York

  • Research Site - New York

North Carolina

  • Research Site - Durham

Oregon

  • Research Site - Portland

Texas

  • Research Site - Houston

Ontario

  • Research Site - Toronto

Quebec

  • Research Site - Montreal

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2026-01-09
Est. Completion 2029-02-15
Phase Phase 1
AstraZeneca

1,285 total trials

What NCT07155226 shows while recruiting

NCT07155226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher).

The record links to 3 conditions, with Higher-risk Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which AZD3632 is the first listed.

NCT07155226 names 20 study sites across 8 states, led by Other, Illinois, New York.

Frequently Asked Questions

What is clinical trial NCT07155226 about?

NCT07155226 is a clinical study titled "Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression". The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (...

What is the current status of trial NCT07155226?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2026-01-09. Estimated completion is 2029-02-15.

What conditions does trial NCT07155226 study?

This clinical trial studies the following conditions: Higher-risk Myelodysplastic Syndromes, Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia.

What interventions are being tested in trial NCT07155226?

The interventions under investigation include: AZD3632 (DRUG), Posaconazole (DRUG).

Who is sponsoring clinical trial NCT07155226?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07155226 being conducted?

This trial has 20 study locations across Illinois, New York, North Carolina, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Higher-risk Myelodysplastic Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07155226's enrollment target sits among peer trials

84 660th of 2000 higher than 1,336 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02391519 · 84 participants

    Effects of High Altitude on AMPK Activation

  • NCT03838536 · 84 participants · NA

    Synergistic Activity of Human Milk Nutrients and Infant Cognition

  • NCT03884075 · 84 participants · Phase 2

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

  • NCT03894917 · 84 participants

    Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07155226

Source: ClinicalTrials.gov NCT07155226, the US trial registry maintained by the National Library of Medicine. NCT07155226 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.